These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 32574023)

  • 1. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
    Stein Gold LF; Takiya L; Zang C; Sanders P; Feldman SR
    J Drugs Dermatol; 2020 Jun; 19(6):619-624. PubMed ID: 32574023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF; Stein Gold LF; Lynde C; Guenther L; Greenberger S; Chu CY; Ghodsi Z; Vlahos B; Sanders P; Cha A; Canosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L; Tao X; Liu S; Cheng H; Fang R; Zhao Y; Cha A; Encinas GA; Zhou Y; Deng Y; Zhang J
    Dermatol Ther (Heidelb); 2024 May; 14(5):1229-1243. PubMed ID: 38748345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs.
    Cao XC; Lu JW; Feng YF; Song LB; Lu Y
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4657-4662. PubMed ID: 38358466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    Silverberg JI; Kirsner RS; Margolis DJ; Tharp M; Myers DE; Annis K; Graham D; Zang C; Vlahos BL; Sanders P
    J Am Acad Dermatol; 2024 May; 90(5):945-952. PubMed ID: 38340127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.
    Ryan Wolf J; Chen A; Wieser J; Johnson B; Baughman L; Lee G; Pope E; Franco A; Love T; Beck LA
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1364-1372. PubMed ID: 38357778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy of 2% crisaborole ointment on chronic hyperplasia lesions in 49 patients with atopic dermatitis.
    Ma C; Sun J; Liu Z; Zhang C
    Int J Dermatol; 2024 Mar; ():. PubMed ID: 38546047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 4 Inhibitors, Basophils, and Atopic Dermatitis.
    Das M; Mukherjee S; Geha RS
    J Invest Dermatol; 2024 May; 144(5):924-926. PubMed ID: 38441508
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Dermatitis; 2024 Mar; ():. PubMed ID: 38513053
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF; Yosipovitch G; Stein Gold LF; Kalabis M; Zang C; Vlahos B; Sanders P; Myers DE; Bushmakin AG; Cappelleri JC; Olivadoti M; Paller AS
    Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
    Ammirati E; Frigerio M; Adler ED; Basso C; Birnie DH; Brambatti M; Friedrich MG; Klingel K; Lehtonen J; Moslehi JJ; Pedrotti P; Rimoldi OE; Schultheiss HP; Tschöpe C; Cooper LT; Camici PG
    Circ Heart Fail; 2020 Nov; 13(11):e007405. PubMed ID: 33176455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Training and validation of a deep learning architecture for the automatic analysis of coronary angiography.
    Du T; Xie L; Zhang H; Liu X; Wang X; Chen D; Xu Y; Sun Z; Zhou W; Song L; Guan C; Lansky AJ; Xu B
    EuroIntervention; 2021 May; 17(1):32-40. PubMed ID: 32830647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP; Zang C; Neary MP; Bushmakin AG; Cappelleri JC; Cha A; Russo C; Luger TA
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):845-853. PubMed ID: 33728583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin permeation and penetration of crisaborole when coapplied with emollients.
    Draelos ZD; Ports WC; Vlahos B; Yeoh T; Wu-Linhares D; Brown MB; Lenn J; Thombre AG
    J Am Acad Dermatol; 2020 Dec; 83(6):1801-1803. PubMed ID: 33069458
    [No Abstract]   [Full Text] [Related]  

  • 15. Repigmentation in a patient with vitiligo on crisaborole 2% ointment.
    Tam I; Kahn JS; Rosmarin D
    JAAD Case Rep; 2021 May; 11():99-101. PubMed ID: 33948468
    [No Abstract]   [Full Text] [Related]  

  • 16. The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.
    Napolitano M; Fabbrocini G; Ruggiero A; Marino V; Nocerino M; Patruno C
    Drug Des Devel Ther; 2021; 15():1135-1147. PubMed ID: 33731985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter to the Editor Regarding 'Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis'.
    Luger T; Ranjan S
    Dermatol Ther (Heidelb); 2021 Apr; 11(2):639-642. PubMed ID: 33660231
    [No Abstract]   [Full Text] [Related]  

  • 18. A rare case of lichen simplex chronicus in an adolescent female successfully managed with Crisaborole.
    Wei G; Rodriguez-Waitkus P; Soylu L
    Dermatol Ther; 2021 Mar; 34(2):e14752. PubMed ID: 33406311
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
    Geng B; Hebert AA; Takiya L; Miller L; Werth JL; Zang C; Sanders P; Lebwohl MG
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1667-1678. PubMed ID: 34379285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.